Sam H.A. Muller , Tessa I. van Rijssel , Ghislaine J.M.W. van Thiel, The Hypermarker Consortium , The Trials@Home Consortium
{"title":"Diffused responsibilities in technology-driven health research: The case of artificial intelligence systems in decentralized clinical trials","authors":"Sam H.A. Muller , Tessa I. van Rijssel , Ghislaine J.M.W. van Thiel, The Hypermarker Consortium , The Trials@Home Consortium","doi":"10.1016/j.drudis.2025.104309","DOIUrl":null,"url":null,"abstract":"<div><div>Innovations such as artificial intelligence (AI) and decentralized clinical trials (DCTs) offer opportunities to enhance trial quality and efficiency. However, these innovations raise ethical questions about key responsibilities in research, such as participant safety and data quality. Using an example of an AI system determining personalized medication dosages in a DCT, we highlight how these technologies diffuse responsibilities among multiple actors and technologies. Diffusion diminishes the ability of actors to fulfill responsibilities. To address this, leading actors, such as sponsors, should prioritize overseeing responsibility attribution and implementation. This involves mapping responsibilities, identifying risks and challenges for fulfilling these responsibilities, and organizing adequate communication channels.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 2","pages":"Article 104309"},"PeriodicalIF":6.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625000224","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Innovations such as artificial intelligence (AI) and decentralized clinical trials (DCTs) offer opportunities to enhance trial quality and efficiency. However, these innovations raise ethical questions about key responsibilities in research, such as participant safety and data quality. Using an example of an AI system determining personalized medication dosages in a DCT, we highlight how these technologies diffuse responsibilities among multiple actors and technologies. Diffusion diminishes the ability of actors to fulfill responsibilities. To address this, leading actors, such as sponsors, should prioritize overseeing responsibility attribution and implementation. This involves mapping responsibilities, identifying risks and challenges for fulfilling these responsibilities, and organizing adequate communication channels.
期刊介绍:
Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.
Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.